This study will evaluate the skin pharmacokinetics and tolerability of bimatoprost Formulation A and Formulation B following 14 days of once daily topical administration in male participants with androgenetic alopecia (AGA).
Single-center, multiple-dose study evaluting the local pharmacokinetics and tolerability of bimatoprost following 14 days of once daily topical administration of bimatoprost Formulation A and Formulation B (both containing 1% bimatoprost) to the scalp of male patients With androgenetic alopecia
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
11
Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.
Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.
DermResearch, LLC
Austin, Texas, United States
Drug Concentration in Skin Biopsy Samples
Time frame: Day 14
Percentage of Participants with at Least 1 Treatment Emergent Adverse Event
Time frame: 28 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.